At the DIA Global 2024 Conference, Dr. Peter Marks, director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA), and Lori Ellis, head of insights at BioSpace, discussed the advancements being made to help drive forward drug and medical device development. Not surprisingly, Dr. Marks stressed the need for regular communication between the FDA and the biopharma industry as science and technology continue to evolve.
